Home Business Bayer promotes “hybrid” equity incentives, Boten shares win orders from U.S. pharmaceutical companies_Company_Growth_Customer

Bayer promotes “hybrid” equity incentives, Boten shares win orders from U.S. pharmaceutical companies_Company_Growth_Customer

by admin

Original title: Baiya promotes “hybrid” equity incentives and Boten shares win orders from US pharmaceutical companies

Chongqing Commercial Daily-Upstream News Chief Reporter Liu Yong, intern Lai Yaxin

On the evening of November 30th, “Sanitary Napkins First Share” Chongqing Baiya Co., Ltd. (003006) announced that it launched its first equity incentive plan after listing. It plans to grant no more than 4,955,400 rights to 568 middle-level managers and core personnel. Accounted for 1.1584% of the company’s total share capital, of which 1,689,800 were stock options with an exercise price of RMB 17.38 per share; 3,265,600 shares were restricted stocks with a grant price of RMB 8.69 per share.

This is the first time that the same equity incentive plan mixes stock options and restricted stocks in a Chongqing listed company, and it is rare in China.

Baiya shares stated that this move is to further improve the corporate governance structure, establish and improve a long-term incentive mechanism, attract and retain outstanding talents, effectively combine the interests of shareholders, the company and employees, and pay attention to the long-term development of the company.

In the main performance unlocking conditions, Baiya shares the assessment requirements into “online” and “offline” two situations. If the incentive targets are employees of the company and its holding subsidiaries responsible for online business, the assessment target is based on online business operating income in 2020, and the growth rate of online business operating income from 2022 to 2024 is not less than 120% and 220 respectively. % And 350%; if the incentive object is non-online business employees, based on the company’s operating income and net profit in 2020, the operating income growth rate from 2022 to 2024 shall not be less than 45%, 75% and 115% respectively; The growth rate of net profit shall not be less than 40%, 65% and 95% respectively.

Baiya’s operating income in 2020 was 1.251 billion yuan, an increase of 8.82% year-on-year; the net profit attributable to shareholders of listed companies was 183 million yuan, an increase of 42.41% year-on-year. In the first three quarters of 2021, operating income was 1.084 billion yuan, a year-on-year increase of 19.56%; net profit attributable to shareholders of listed companies was 173 million yuan, a year-on-year increase of 33.31%.

Pharmaceutical customization stock Boton (300363) announced that it has recently received a new batch of “Purchase Orders” from a large US pharmaceutical company. The order is a custom-made research and development manufacturing (CDMO) service order related to a small molecule innovative drug. As of the order delivery date, the company has received a total of US$217 million in orders for related products in the past 12 consecutive months, which is more than 50% of the company’s audited operating income in the most recent fiscal year.

Boten shares stated that it is inconvenient to disclose customer and product-related information in accordance with the relevant agreements signed between the company and the customer due to the involvement of customer trade secrets. The company’s sales to this customer in the past three years are as follows: In 2018, the customer’s revenue was 37.82 million yuan, accounting for 3.19% of the year’s operating revenue; in 2019, the customer’s revenue was 58.46 million yuan, accounting for 3.77% of the year’s operating revenue; in 2020, the customer The revenue was 103 million yuan, accounting for 4.99% of the operating revenue that year.

The above order is effective from the date of receipt by the company, and the current order has been effective; the order delivery time is from 2021 to 2022. In this regard, Proton said that the execution of the order is expected to have a positive impact on the company’s operating revenue and operating profit in 2021 and 2022. The company will recognize revenue in the corresponding accounting period based on the execution of the order and the principle of revenue recognition.

In the first three quarters of 2021, Boton Co., Ltd. achieved operating income of 2.030 billion yuan, a year-on-year increase of 36.41%; net profit attributable to shareholders of listed companies was 361 million yuan, a year-on-year increase of 50.92%; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was 353 million Yuan, an increase of 60.61%. Return to Sohu to see more

Editor:

Disclaimer: The opinions of this article only represent the author himself. Sohu is an information publishing platform. Sohu only provides information storage space services.

.

0 comment
0

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy